Mayne Pharma Group Limited

MYX

AU000000MYX0

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:24 2025-06-20 am EDT			5-day change	1st Jan Change
5.030 ^AUD	-3.27%		-3.27%	+1.21%

Jun. 18	Australian Shares Flat; Mayne Pharma Shareholders Approve Proposed Cosette Takeover	MT
Jun. 18	Mayne Pharma Group Limited - Shareholder/Analyst Call

Mayne Pharma slumps 30% as Cosette threatens to scrap $432 million deal

Published on 05/20/2025 at 22:03

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Mayne Pharma Group Limited

Australian Shares Flat; Mayne Pharma Shareholders Approve Proposed Cosette Takeover	Jun. 18	MT
Mayne Pharma Group Limited - Shareholder/Analyst Call	Jun. 18
Mayne Pharma Shareholders Approve Proposed Cosette Takeover	Jun. 18	MT
Mayne Pharma Says 89.64% Shareholders At Scheme Meeting Voted In Favour Of Scheme Resolution	Jun. 17	RE
Mayne Pharma, Cosette Agree to Timetable for Court Proceedings Regarding Purported Acquisition Termination	Jun. 15	MT
Mayne Pharma Reports Commencement of Court Proceedings Against Cosette	Jun. 15	RE
Mayne Pharma Receives Further Purported Notice To Terminate Scheme Implementation Deed From Cosette	Jun. 13	RE
Mayne Pharma Deems Termination Notice for Potential Acquisition From Cosette Pharmaceuticals as Invalid	Jun. 13	MT
Mayne Pharma Continues to Recommend Shareholders Accept Scheme Implementation Deed With Cosette; Shares Rise 3%	Jun. 04	MT
Mayne Pharma Says Directors Unanimously Recommend Shareholders Vote In Favour Of Scheme	Jun. 04	RE
Mayne Pharma Receives Purported Notice To Terminate SID	Jun. 04	RE
Mayne Pharma Receives Cosette's Purported Termination Notice; Shares Fall 9%	Jun. 04	MT
Mayne Pharma Says 10 Business Day Consultation Period Asserted By Cosette Now Expired	Jun. 03	RE
Mayne Says Cosette Consultation Period Expires Without Termination Notice; Shares Up 4%	Jun. 03	MT
Mayne Pharma Group Unit Seeks Over $11.5 Million in Damages in US Court Complaint Against TherapeuticsMD	Jun. 01	MT
Mayne Pharma Posts Update On US Legal Proceeding With Therapeuticsmd Inc	Jun. 01	RE
Mayne Pharma slumps 30% as Cosette threatens to scrap $432 million deal	May. 21	RE
Mayne Pharma slumps 30% as Cosette threatens to scrap $432 million deal	May. 20	RE
Mayne Pharma Rejects Claim of Material Adverse Change; Shares Fall 30%	May. 20	MT
Mayne Pharma Gives Update On Scheme With Cosette Pharmaceuticals	May. 20	RE
Mayne Pharma Group Enters Trading Halt Ahead of Acquisition Disclosure	May. 18	MT
Mayne Pharma Seeks Trading Halt Pending Announcement In Relation To Proposed Acquisition	May. 18	RE
New South Wales Supreme Court Orders Meeting for Mayne Pharma's Proposed Acquisition by Cosette; Shares Jump 12%	May. 15	MT
Mayne Pharma Group to Respond to US FDA Letter Within Prescribed Timeframe	May. 14	MT
Mayne Pharma Group Trading Suspended After 12% Share Drop	May. 14	MT

Chart Mayne Pharma Group Limited

Duration

Period

MYX: Dynamic Chart

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company also provides contract development and manufacturing services to clients worldwide. The Companyâs segments include Womenâs Health, Dermatology, and International. The Womenâs Health segment distributes womenâs health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others.

Employees

967

Sector

Pharmaceuticals

Calendar

Aug. 20 - Q4 2025 Earnings Release (Projected)

More about the company